C. Yang

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced non-squamous non-small cell lung cancer.

M. Nishio, N. Yamamoto, T. Tamura, 2021, Annals of Oncology.

PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study

N. Reinmuth, T. Mok, Melissa L. Johnson, 2021, Journal of Thoracic Oncology.

OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC

E. Garon, S. Kim, M. Hussein, 2022, Journal of Thoracic Oncology.

First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis

T. Hsia, F. Branle, P. Yu, 2019, Annals of Oncology.

1208P Final results of APOLLO study: Overall survival (OS) of aumolertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)

H. Pan, R. Guo, Han Yang, 2021, Annals of Oncology.